Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy

Not yet recruitingOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

December 30, 2025

Conditions
Squamous Cell Carcinoma of the Skin
Interventions
OTHER

Peripheral blood sampling in order to evaluate changes in the circulating immune population

Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)

All Listed Sponsors
collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

collaborator

Azienda Ospedaliera di Padova

OTHER

collaborator

Istituti Ospitalieri di Cremona

OTHER

collaborator

IRCCS Sacro Cuore Don Calabria di Negrar

OTHER

collaborator

ASST Bergamo Ovest

OTHER

collaborator

San Gerardo Hospital

OTHER

collaborator

ASST Valcamonica

UNKNOWN

lead

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

OTHER